TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04512976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (no cooling modalities)
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (no cooling modalities)
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (no cooling modalities)
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (no cooling modalities)
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (no cooling modalities)
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modality.
Study: NCT06034366

Intervention type: OTHER
Group type: OTHER
Intervention: 0.9% sodium chloride
Description: placebo eye drops (0.9% sodium chloride, 3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks
Study: NCT05725603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI imaging
Description: Shoulder MRI will be performed at least 3 years after shoulder surgery
Study: NCT05501197

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy via video conference
Description: The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy via mobile application
Description: The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch
Study: NCT06142279

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Sampling
Description: At baseline, nasal, salivary and blood sampling will be taken for the participants.
Study: NCT04512976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (no cooling modalities)
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Spray Only
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the skin wetting modality.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Spray Only
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the skin wetting modality.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.
Study: NCT06142279

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Sampling
Description: At baseline, nasal, salivary and blood sampling will be taken for the participants.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCR (polymerase chain reaction) SARS-CoV-2
Description: At baseline, this PCR SARS-CoV-2 will be taken for the participants.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCR (polymerase chain reaction) SARS-CoV-2
Description: At baseline, this PCR SARS-CoV-2 will be taken for the participants.
Study: NCT06498973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tagraxofusp-erzs
Description: Given IV
Study: NCT05271929

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Current standard of care and COVID-19 convalescent and vaccinated plasma
Description: ABO compatible convalescent plasma infused intravenously on study day 1 (as soon as possible after randomisation) and the second on day 1 or day 2. Plasma obtained by apheresis from donors who have recovered from COVID-19 infection (at least 14 days after recovery) and have been vaccinated (at least 3 weeks after first dose of vaccine). A combination of both a SARS-CoV-infection and a SARS-CoV-2 vaccination of the donor is required - irrespective of the sequence of infection and vaccination. As far as the availability of CCP units allows, the two plasma units should have been donated by two different convalescents.
Study: NCT05271929

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current standard of care
Description: Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~* Casirivimab~* Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~* Imdevimab~* Sotrovimab (Xevudy)~* Tixagevimab / Cilgavimab (Evusheld)~* Molnupiravir (MK-4482)~* Nirmatrevlir / Ritonavir (Paxlovid)~* Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms.
Study: NCT04512976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Spray and Fan
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to both the skin wetting and fan cooling modalities.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.
Study: NCT06055088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand and foot exercise
Description: The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week.~Patients in the massage ball group will be given a massage ball to be used in exercises. Patients in the stress ball group will be given a stress ball to be used in exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand and foot exercise
Description: The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week.~Patients in the massage ball group will be given a massage ball to be used in exercises. Patients in the stress ball group will be given a stress ball to be used in exercises.
Study: NCT04512976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Spray and Fan
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to both the skin wetting and fan cooling modalities.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Spray and Fan
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to both the skin wetting and fan cooling modalities.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Spray and Fan
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to both the skin wetting and fan cooling modalities.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Spray and Fan
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to both the skin wetting and fan cooling modalities.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Spray and Fan
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to both the skin wetting and fan cooling modalities.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.
Study: NCT05872451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: After measuring the initial current intensity, quantitative neuromuscular blockade monitoring is applied, and rocuronium (0.6 mg/kg) is administered.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nerve stimulator
Description: Measuring the minimum current intensity for the stimulation of the obturator nerve to show the contraction of the adductor longus muscle.
Study: NCT06055894

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: For 2 weeks, patients will receive omega 3 fatty acid supplements 1640 mg (2 capsules) twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: For 2 weeks, patients in the curcumin arm will receive Curcumin C3 complex 1000 mg with 5 mg BioPerine twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: For 2 weeks, patients in the probiotic arm will receive Ultra-50 probiotics with 50 billion CFU per capsule (one capsule) twice daily
Study: NCT06072066

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skin Barrier Oral Supplement
Description: Supplment powder
Study: NCT05932199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab / tremelimumab
Description: Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
Description: Cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 will be provided as per standard of care.~Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL.
Study: NCT05971108

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Elecsys® GAAD
Description: Elecsys® GAAD is a CE marked in vitro diagnostic (IVD) multivariate index assay, intended as an aid in the diagnosis of early-stage HCC. It provides a semi quantitative result by combining in an algorithm the quantitative measurements of Elecsys® AFP (alpha-fetoprotein) and Elecsys® PIVKA-II (protein induced by vitamin K absence II) levels in serum and plasma, with gender and age. Clinical evidence showed that Elecsys® GAAD had high performance in detecting HCC (sensitivity 86.5%), particularly early stage (sensitivity 78.9%), with 91.4% specificity for both early and all stages, out-performing current standard of care (Chan et al. 2021). Elecsys® GAAD may be integrated into current surveillance practice to increase early-stage HCC detection rate, reduce unnecessary onward investigations and patient anxiety.
Study: NCT06572475

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: USPIO enhanced MRI
Description: Ferumoxytol (Feraheme©, AMAG pharmaceuticals, US) enhanced MRI
Study: NCT06716970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril/valsartan 200mg
Description: Sacubitril/valsartan 200mg QD
Study: NCT06055894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole food, plant-based diet (WFPBD)
Description: Daily Harvest once a week. The meals will have range from 2 breakfast, 11 lunch/dinners, 1 snack (provided Week 1), and whole grains items (provided Week 2).
Study: NCT06013423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05446909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBMT mindfulness
Description: IBMT is an effortless mindfulness technique; health education is a class including health-related topics - exercise, sleep, nutrition, lifestyle, stress management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health education
Description: Health education includes health-related topics - exercise, sleep, stress management, nutrition, lifestyle
Study: NCT04616781

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
Description: nutritional ketone ester

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric dextrose placebo
Description: Drink indistinguishable from ketone ester

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol drinks
Description: drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
Study: NCT04616781

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol drinks
Description: drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
Study: NCT05607992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief exposure-based CBT
Description: The 5-week intervention is psychologist-guided and delivered via text-based interactive online treatment modules, where patients complete weekly homework assignments and have regular online contact with psychologists with training in CBT for cardiac disease. Key components include imaginal exposure of the ACS event, interoceptive exposure through at home physical activity that stimulats the CV system, exposure in-vivo to reduce avoided situations, and activities to enhance physical activity wellbeing. Labeling (i.e., describing cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure.
Study: NCT05834543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin
Description: TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penpulimab injection, Paclitaxel, Cisplatin
Description: Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection, Penpulimab injection, TQB3617capsules
Description: TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).
Study: NCT05651009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TKA
Description: Total knee artroplasty with medial parapatellar incision and mechanical alignment without navigation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TKA
Description: Total knee artroplasty with medial parapatellar incision and mechanical alignment without navigation
Study: NCT04911725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic Compression Prototype
Description: Elastic Compression device - No medical, surgical or laboratory procedure is implied in the use of the IMD.
Study: NCT06013423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate
Study: NCT04920851

Intervention type: DEVICE
Intervention: cytokine hemadsorption
Description: to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.

Intervention type: DEVICE
Intervention: cytokine hemadsorption
Description: to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.
Study: NCT04452188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normoxia (with controlled re-oxygenation)
Description: Participants will receive lower levels of oxygen during surgery and after surgery on the ventilator.~As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation with an FiO2 of 50% or less (unless clinically necessary) to achieve oxygen saturation and PaO2 goals that fit within the expected range for the participant's physiology:~1. Single ventricle patients (PaO2:35-45 and oxygen saturation 75%-85%)~2. Two ventricle patients (PaO2: 60-100 and oxygen saturation \>92%)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care ventilation
Description: As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation per standard protocols. Ventilation will be continued in the ICU and adjusted per standard goals per the intensivist.
Study: NCT06098950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI model biased against pneumonia
Description: In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against pneumonia, always predicting that pneumonia is present with high likelihood in survey vignette patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses (heart failure, COPD).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI model biased against pneumonia
Description: In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against pneumonia, always predicting that pneumonia is present with high likelihood in survey vignette patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses (heart failure, COPD).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI model biased against COPD
Description: In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against COPD, always predicting that COPD is present with high likelihood in survey vignette patients where a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses (heart failure, pneumonia).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI model biased against COPD
Description: In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against COPD, always predicting that COPD is present with high likelihood in survey vignette patients where a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses (heart failure, pneumonia).
Study: NCT06413810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calmarell
Description: Food ingredient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded placebo
Study: NCT06013423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Receive IV
Study: NCT04871334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TWP-101
Description: IV infusion Q2W for 4 weeks (28-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TWP-101
Description: IV infusion Q2W for 4 weeks (28-day cycles)
Study: NCT06409624

Intervention type: OTHER
Intervention: No intervention is planned as part of the study
Description: No intervention is planned as part of the study

Intervention type: OTHER
Intervention: No intervention is planned as part of the study
Description: No intervention is planned as part of the study
Study: NCT05301335

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SCONE
Description: The Spinal COrd NEuromodulation(SCONE) device delivers a sufficient electrical signal non-invasively to activate the neural structures of the spinal cord without cutaneous discomfort. Rather than relying on stimulation of peripheral nerves, SCONE modulates the CNS directly via the spinal cord. Importantly, SCONE is a technique that enables electrical stimulation of the spinal cord without the need for insertion or implantation of stimulating electrodes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCONE
Description: The Spinal COrd NEuromodulation(SCONE) device delivers a sufficient electrical signal non-invasively to activate the neural structures of the spinal cord without cutaneous discomfort. Rather than relying on stimulation of peripheral nerves, SCONE modulates the CNS directly via the spinal cord. Importantly, SCONE is a technique that enables electrical stimulation of the spinal cord without the need for insertion or implantation of stimulating electrodes